Streetbeat News

Products Services

AVXL

Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug blarcamesine to the European Medicines Agency (EMA) for the treatment of Alzheimer's Disease. This marks the first marketing authorization submission for blarcamesine.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

VGLT

The article discusses the potential impact of Trump's second term on trade policies and fiscal reforms, highlighting the VGLT ETF as a potential opportunity. While VGLT may appreciate, investors should be cautious of risks such as inflation, budget deficits, and tariffs. Long-term bonds could benefit from potential Fed rate cuts, especially in a recession scenario.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

HRMY

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential violations of federal securities laws, following a report by Scorpion Capital raising concerns about their narcolepsy drug, Wakix.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

SMTC

Semtech's Q3 earnings report highlights a strong turnaround with significant revenue growth and improved margins. Despite a $1 billion net debt, the company's innovative products in high-growth markets like data centers and IoT suggest strong future cash flow potential. The stock is priced at 33x forward free cash flow, which is considered fair given the expected 30% year-over-year revenue growth and potential $200 million EBITDA.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

OCUL

Ocular Therapeutix, Inc. (NASDAQ: OCUL) will participate in several investor and scientific conferences in December, showcasing their innovative therapies for retinal diseases and other eye conditions.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

THTX

Theratechnologies has resubmitted its supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin to the FDA. This resubmission addresses concerns from a previous Complete Response Letter. The F8 formulation aims to replace EGRIFTA SV® with a simplified dosing regimen for treating excess abdominal fat in adults with HIV and lipodystrophy.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

HCNWF

Hypercharge Networks Corp. reported record revenue growth for Q2 2025, with a 50% year-over-year increase to $1.4 million and a 235% increase in sales backlog to $8.7 million. The company also delivered a record 615 charging ports, marking a 116% year-over-year increase.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

BINP

Bionoid Pharma, Inc. (OTC PINK:BINP) is revolutionizing the sales and communication industry with its AI Maverick platform, which automates sales processes and reduces the need for Sales Development Representatives (SDRs).

Portfolio Pulse from

November 26, 2024 | 12:45 pm

NGNE

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential violations of federal securities laws. This follows a press release by Neurogene reporting interim clinical data from a Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

LGO

Largo has filed a technical report for its updated life of mine plan and pre-feasibility study for its vanadium-titanium operation in Brazil. This development is significant for the company's operations and future planning.

Portfolio Pulse from

November 26, 2024 | 12:45 pm